Optometrists in Elizabethtown, KY Accepting Medicare

28 Optometrists found. Showing 21 - 28

Dr. Hiral Patel Badiwala, O.D. Optometrist - Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 2618 Ring Rd Ste 108, Elizabethtown, KY 42701 Phone: 270-765-1128

Dr. Sarah Rae Byrd, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1109 Woodland Dr, Elizabethtown, KY 42701 Phone: 270-765-6066

Ward Family Eye Care Pllc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 100 Walmart Dr, Elizabethtown, KY 42701 Phone: 270-737-0055    Fax: 270-763-0050

Dr. Sarah Gallagher Krein, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 103 Diecks Dr, Elizabethtown, KY 42701 Phone: 270-769-1397    Fax: 270-765-4899

Dr. Mattie Katherine Adams, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1000 Johnstown Rd Ste 102, Elizabethtown, KY 42701 Phone: 270-769-0099    Fax: 270-763-0315

Dr. Sara Rene' Borders, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1609 N Dixie Ave, Elizabethtown, KY 42701 Phone: 270-765-7372

William Jason Ward, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 100 Walmart Dr, Elizabethtown, KY 42701 Phone: 270-737-0055    Fax: 270-763-0050

Borders Eyecare Specialists Pllc Optometrist Medicare: Medicare Enrolled Practice Location: 611 W Poplar St Ste C4a, Elizabethtown, KY 42701 Phone: 270-872-8108

News Archive

YM Biosciences to present JAK1/2 inhibiting small molecule and vascular disrupting agent data at Cancer Conference

YM BioSciences Inc., is presenting posters on its JAK1/2 inhibiting small molecule (CYT387) and on its novel vascular disrupting agent (CYT997) at the Lorne Cancer Conference in Lorne, Victoria, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 kinases by Dr. Andrew Wilks, the founder of Cytopia Limited, now YM Australia. CYT997 is an orally-available agent with dual mechanisms of vascular disruption and cytotoxicity and has the potential to be broadly active against a range of tumor types.

Medline Industries signs exclusive distribution agreement with Derma Sciences for BIOGUARD Barrier Dressings

Derma Sciences, Inc., a specialty medical device and pharmaceutical company focused on advanced wound care, today announced that it has signed an exclusive distribution agreement with Medline Industries for sales of one of its key products – BIOGUARD™ Barrier Dressing – into the acute care market. Medline is the 2nd leading provider of traditional wound care products into Acute Care facilities, with over 800 sales representatives. Sales will begin this month.

New orthotopic model recapitulates more closely metastatic steps in Ewing sarcoma

The Sarcoma research group of Bellvitge Biomedical Research Institute, led by Dr. Òscar Martínez-Tirado, has developed a modified version of an orthotopic model that allows researchers to recreate more closely the metastatic steps in Ewing sarcoma (ES), the second most common bone tumor in children and adolescents.

Blaze Bioscience to initiate first Phase 1 clinical study of BLZ-100 in patients with skin tumors

Blaze Bioscience, Inc. and its subsidiary, Blaze Bioscience Australia Pty Ltd, today announced the initiation of the first Phase 1 clinical study of the first Tumor Paint product candidate, BLZ-100. The study, titled "A Phase I Dose Escalation/Expansion Study of BLZ-100 Administered by Intravenous Injection in Adult Subjects with Skin Cancer," will enroll up to 30 patients with basal cell carcinoma, squamous cell carcinoma, or amelanotic melanoma.

Read more Medical News

› Verified 2 days ago

• 1
• 2(current)